Precision BioSciences, Inc.
(NASDAQ : DTIL)

( )
DTIL After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -16.36%57.710.0%$1537.44m
GILDGilead Sciences, Inc. -0.22%73.181.0%$1287.43m
AMGNAmgen, Inc. -1.78%222.401.3%$637.47m
REGNRegeneron Pharmaceuticals, Inc. -4.33%545.212.5%$616.99m
NVAXNovavax, Inc. 4.47%48.17102.0%$608.66m
VRTXVertex Pharmaceuticals, Inc. -6.48%266.501.9%$516.32m
BIIBBiogen, Inc. -2.84%295.871.6%$413.02m
ILMNIllumina, Inc. -0.08%354.413.5%$354.75m
SRNESorrento Therapeutics, Inc. 3.95%5.271.8%$307.06m
SGENSeattle Genetics, Inc. -2.59%151.736.1%$243.04m
ALXNAlexion Pharmaceuticals, Inc. 1.28%102.802.0%$224.06m
AAgilent Technologies, Inc. 1.37%86.141.6%$196.15m
CODXCo-Diagnostics, Inc. -2.80%18.030.0%$185.93m
MGNXMacroGenics, Inc. -6.82%23.646.2%$178.27m
BMRNBioMarin Pharmaceutical, Inc. 6.39%103.744.3%$172.63m

Company Profile

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.